Understand · Discuss · Plan together

Lynch Syndrome and Hereditary Colorectal Cancer

Lynch syndrome is a DNA-repair condition that can affect more than the bowel.

Chapter 5 of 16

5 of 16
Explore all 16 chapters

The genes and cancer pattern

Lynch syndrome involves pathogenic germline variants in MLH1, MSH2, MSH6 or PMS2, or certain EPCAM deletions that affect MSH2. Risks vary substantially by gene. Colorectal and endometrial cancers are central; ovarian, stomach, urinary-tract and other cancers may also be relevant.

Tumour tests are a starting point

Mismatch-repair immunohistochemistry (MMR IHC) checks repair proteins in tumour tissue. Microsatellite instability (MSI) testing assesses a consequence of repair failure. An abnormal result does not by itself prove Lynch syndrome. Loss of MLH1/PMS2 may require MLH1 promoter methylation testing; BRAF testing can help in colorectal cancer but is not the equivalent triage test for endometrial cancer. The genetics team decides whether germline or additional tumour testing is needed.

Not every hereditary bowel cancer is Lynch

Familial adenomatous polyposis (FAP), usually involving APC, can cause many adenomas. MUTYH-associated polyposis typically involves harmful changes in both gene copies. Other polyposis syndromes have different inheritance and surveillance. Having only one MUTYH variant is not the same diagnosis as MUTYH-associated polyposis.

Why prevention is different

Lynch surveillance uses scheduled colonoscopy, often every 1–2 years depending on the selected guideline and gene. A stool test is not an equivalent substitute. Polyp removal can prevent some cancers, but surveillance cannot prevent every cancer. The specialist plan should specify the gene, starting age, interval and review date.

What to bring

  • Pathology and the complete MMR IHC or MSI report.
  • Any methylation, BRAF and germline reports already performed.
  • Colonoscopy and polyp pathology reports, plus the family history.

Sources and further reading

Accessible sources checked: 19 October 2026. International recommendations are identified where used; care in India requires individual clinical assessment. No claim is made to have directly verified restricted NCCN guidance.